| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6061594 | Annals of Allergy, Asthma & Immunology | 2014 | 7 Pages |
Abstract
Recent insight into the immunopathology of respiratory diseases should be used to identify patient populations likely to respond to anti-IgE therapy. Controlled clinical trials are needed to confirm efficacy and determine the clinical significance of the effects of omalizumab in these populations.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Matteo MD, PhD, Giuseppe MD, Pierluigi MD, Andrea MD, GianEnrico MD, Massimo MD, PhD, Giorgio Walter MD,